$865.97
8.50.99%
At Close: -
$867.00
1.030.12%
After Hours: 7:55 PM EDT
15 minutes delayed
Comments
Loading...
Eli Lilly and Co
LLYNYSE
Latest news for Eli Lilly and Co (NYSE:LLY) Stock
Eli Lilly and Co Stock (NYSE: LLY)
Categories: All
Monday, July 22, 2024
Friday, July 19, 2024
- Craze For Ozempic And Zepbound For Weight Loss Leave Diabetic Patients Without Critical GLP-1 Medications
- Benzinga Market Summary: Microsoft And Airlin...
- Eli Lilly shares are trading higher after Zep...
- Eli Lilly's Famed Weight Loss Drug Zepbound Scores Chinese Approval
- Palantir, Netflix, Domino's Pizza, Eli Lilly, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Thursday, July 18, 2024
- EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
- Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst
- VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday?
- What's Going On With Eli Lilly And Company Shares Thursday?
- Teva's Migraine Treatment Found Effective For Children As Young As 6
- Shares of weight loss stocks are trading lowe...
Wednesday, July 17, 2024
- Pfizer And Roche Advance On Their Weight Loss Drug Journeys
- Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
- Benzinga Market Summary: Chip Stocks Fall On ...
- Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There'
- Eli Lilly and Novo Nordisk shares are trading...
Tuesday, July 16, 2024
Monday, July 15, 2024
Friday, July 12, 2024
- With Oral Anti-Obesity Candidate Development, Pfizer Seeks Relevant And Competitive Presence - Goldman Sachs
- In-Depth Analysis: Eli Lilly and Co Versus Competitors In Pharmaceuticals Industry
- Using Ozempic, Zepbound Or Other Weight Loss Drugs? Inform Doctors Before Anesthesia Or Surgery, European Medicines Agency Issues Advisory
- Novo Nordisk's 'Miracle' Weight Loss Drug Ozempic Linked To 48% Lower Risk Of Dementia, Study Finds
Thursday, July 11, 2024
- Eli Lilly, Novo Nordisk Shares Dip As Pfizer Ramps Up Diabetes Drug Competition
- Bernie Sanders Targets High Prices of Ozempic and Wegovy In US
- Berenberg Maintains Buy on Eli Lilly and Co, ...
- Shares of Lilly and Novo Nordisk are trading ...
- JP Morgan Maintains Overweight on Eli Lilly a...
- Jim Cramer Identifies Eight Companies Eyeing Trillion-Dollar Club — Elon Musk's Tesla, Eli Lilly Top Contenders
Wednesday, July 10, 2024
- Barclays Maintains Overweight on Eli Lilly an...
- Eli Lilly Announces CFO Change
- 'FTC to Sue Drug Managers over Insulin Prices...
- 10 Health Care Stocks Whale Activity In Today's Session
- Only 25% Patients Stick With Novo Nordisk's Wegovy Or Ozempic After 2 Years, A Study Shows; Company Calls Data Insufficient
- Watching Shares Of Novo Nordisk, Eli Lilly; T...
- Eli Lilly Announces CFO Anat Ashkenazi Resign...
Tuesday, July 09, 2024
- Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst
- Unpacking the Latest Options Trading Trends in Eli Lilly and Co
- S&P 500 Closes At Record High Ahead Of Inflation Data: Fear & Greed Index Remains In 'Neutral' Zone
- Eli Lilly's Mounjaro Outpaces Novo Nordisk's Ozempic In Weight Loss Effectiveness, Study Shows